Correction
Oncology
Miao He, Hai-Gang Sun, Jun-Ying Hao, Yan-Lin Li, Jian-Kun Yu, Yuan-Yuan Yan, Lin Zhao, Na Li, Yan Wang, Xue-Feng BaI, Zhao-Jin Yu, Zhi-Hong Zheng, Xiao-Yi Mi, En-Hua Wang, Min-Jie Wei
Summary: The study showed that silencing of FANCF inhibits the function of the FA/BRCA pathway, resulting in inhibited cell proliferation, increased cell apoptosis, and DNA damage in OVCAR3 cells. Furthermore, silencing of FANCF enhances the antiproliferative effect of ADM in OVCAR3 cells, increases ADM intracellular accumulation, and sensitizes the cells to ADM.
Article
Biotechnology & Applied Microbiology
Dezhang Zhu, Caifeng Shi, Yanan Jiang, Kongjuan Zhu, Xiangzhen Wang, Wei Feng
Summary: Cisatracurium inhibits ovarian cancer cell progression by upregulating lincRNA-p21 expression, which leads to inhibition of cell growth and invasion and induction of apoptosis. Moreover, lincRNA-p21 acts as a regulator by targeting miR-181b, further modulating the biological functions of cancer cells.
Article
Cell Biology
Lin Li, Jie Chen, Ao Wang, Ke Yi
Summary: ALKBH5 regulates the malignant behavior and chemosensitivity of ovarian cancer by regulating PVT1/FOXM1.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Article
Biotechnology & Applied Microbiology
Jing Zhang, Xinyan Xu, Yongfeng Chen, Xiaoju Guan, Hong Zhu, Yuhong Qi
Summary: In this study, the regulatory effect of the CRM1-Survivin axis on the progression of ovarian cancer was explored. The results showed that CRM1 silencing inhibited the proliferation and colony formation of ovarian cancer cells and promoted cell apoptosis by promoting Caspase-3 activation. Survivin was positively regulated by CRM1 and promoted the development of ovarian cancer. This suggests that the CRM1-Survivin axis may serve as a potential therapeutic target for ovarian cancer.
Article
Cell Biology
Cheng Qin, Yuanyang Wang, Bangbo Zhao, Zeru Li, Tianyu Li, Xiaoying Yang, Yutong Zhao, Weibin Wang
Summary: Pancreatic cancer is a lethal disease with low survival rate, and chemotherapy resistance is common. Mitochondria, as the energy source in cancer cells, play a role in chemoresistance. STOML2, located in the inner membrane of mitochondria, is highly expressed in cancer cells. This study found that high STOML2 expression correlated with improved survival in patients with pancreatic cancer. STOML2 inhibited cell proliferation and chemoresistance in pancreatic cancer cells, and was associated with mitochondrial mass and mitophagy. STOML2 stabilized PARL and prevented gemcitabine-induced PINK1-dependent mitophagy, suggesting that targeting STOML2 might enhance gemcitabine therapy in the future.
CELL DEATH & DISEASE
(2023)
Article
Biotechnology & Applied Microbiology
Xuehan Bi, Xiao Lv, Dajiang Liu, Hongtao Guo, Guang Yao, Lijuan Wang, Xiaolei Liang, Yongxiu Yang
Summary: METTL3 promotes the maturation of miR-126-5p through m6A modification, which in turn targets PTEN to activate the PI3K/Akt/mTOR pathway in ovarian cancer progression. This study provides potential targets for future ovarian cancer treatment and reveals tumorigenic mechanisms regulated by m6A modification.
CANCER GENE THERAPY
(2021)
Article
Oncology
Ruyi Li, Yizuo Song, Xin Chen, Man Chu, Zhi-wei Wang, Xueqiong Zhu
Summary: METTL3 overexpression in cervical cancer cells enhances sensitivity to cisplatin and inhibits tumor growth by downregulating RAGE expression.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Cell Biology
Fangfang Li, Chen Zhao, Yuchao Diao, Zixiang Wang, Jiali Peng, Ning Yang, Chunping Qiu, Beihua Kong, Yingwei Li
Summary: The latest research suggests that RNA-binding proteins (RBPs) may be new potential targets for cancer treatment. The study identified MEX3A as an important RBP associated with the clinical prognosis of ovarian cancer. Overexpression of MEX3A promoted proliferation and invasion of ovarian cancer cells, while knockdown suppressed their development and invasion. Additionally, the study revealed TIMELESS as a critical downstream target of MEX3A.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Katherine Tucker, Yajie Yin, Stuart-Allison Staley, Ziyi Zhao, Ziwei Fang, Yali Fan, Xin Zhang, Hongyan Suo, Wenchuan Sun, Varun Vijay Prabhu, Joshua E. Allen, Chunxiao Zhou, Victoria L. Bae-Jump
Summary: ONC206, a chemically modified derivative of ONC201, is a potent inhibitor of cell proliferation and shows anti-tumorigenic effects in ovarian cancer. It has the potential to be an important therapeutic option for ovarian cancer treatment.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Zhiqin Fu, Chao Ding, Wangang Gong, Chao Lu
Summary: Through bioinformatic analysis, we identified RPS6KA2 as the prognosis-related gene of ovarian cancer. The expression of RPS6KA2 was down-regulated in ovarian cancer tissues, and its functions were verified in vitro and in vivo. GSEA analysis revealed the association between RPS6KA2 and the MARK signaling pathway. RPS6KA2 was regulated by miR-19a-3p, miR-106a-5p, and miR-519d-3p, and circFAM169A acted as the common ceRNA of these miRNAs.
FRONTIERS IN ONCOLOGY
(2023)
Article
Reproductive Biology
Haixia Wu, Youliang Yan, Jialin Yuan, Mengze Luo, Yingjian Wang
Summary: Our study found that miR-4324 inhibited FEN1 expression, suppressed cell growth, and increased apoptosis in ovarian cancer cells. Therefore, we identified miR-4324 and FEN1 as potential therapeutic targets for ovarian cancer treatment.
JOURNAL OF OVARIAN RESEARCH
(2022)
Article
Medicine, General & Internal
Yanghui Zhu, Xiaoyu Wang, Zhaoyang Chen, Lingyan Zhou, Xiangjie Di, Ping Fan, Zhiyao He
Summary: In this study, the anti-tumor activity of Anlotinib, a new oral multi-targeted tyrosine kinase inhibitor, against ovarian cancer was investigated. Anlotinib inhibited the proliferation and migration of ovarian cancer cells in vitro, and suppressed tumor growth in a mouse ovarian carcinoma peritoneal metastasis model. These findings suggest that Anlotinib may be a promising therapeutic strategy for ovarian cancer.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Physiology
Muhammad Zaryab Khalid, Zhipeng Sun, Jing Zhang, Shijie Zhang, Guohua Zhong
Summary: Cyromazine has been found to decrease the number of germ cells in livestock and household insect pests by affecting the ecdysone signaling pathway. This finding is important for understanding the mechanism of action of cyromazine.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Anatomy & Morphology
Shan Gong, Bo Bai, Guangyu Sun, Haihong Jin, Zhengmao Zhang
Summary: This study found that CDCA3 was up-regulated in ovarian cancer and knockdown of CDCA3 could inhibit proliferation and migration, enhance sensitivity to cisplatin, and induce apoptosis in ovarian cancer cells. In vivo experiments further confirmed the inhibitory effect of CDCA3 knockdown on tumor growth.
Article
Oncology
Guangxu Xu, Weimin Kong, Ziwei Fang, Yali Fan, Yajie Yin, Stephanie A. Sullivan, Arthur-Quan Tran, Leslie H. Clark, Wenchuan Sun, Tianran Hao, Luyu Zhao, Chunxiao Zhou, Victoria L. Bae-Jump
Summary: The natural product asparagus officinalis exhibits anti-tumorigenic and anti-metastatic effects on serous ovarian cancer cells by decreasing cell viability, inducing apoptosis, and reducing adhesion and invasion abilities. Additionally, it shows synergistic anti-proliferative activity when combined with paclitaxel, and inhibits tumor growth and reduces serum levels of VEGF in a mouse model of ovarian cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Zheng-Hai Tang, Wen-Xiang Cao, Xia Guo, Xiao-Yang Dai, Jia-Hong Lu, Xiuping Chen, Hong Zhu, Jin-Jian Lu
Article
Oncology
Hong Zhu, Dan-Dan Wang, Tao Yuan, Fang-Jie Yan, Chen-Ming Zeng, Xiao-Yang Dai, Zi-bo Chen, Ying Chen, Tianyi Zhou, Guang-Han Fan, Meidan Ying, Ji Cao, Peihua Luo, Xi-Jie Liu, Yuandong Hu, Yong Peng, Qiaojun He, Bo Yang
Article
Multidisciplinary Sciences
Haoyan Li, Yanjia Fang, Chunyi Niu, Hengyi Cao, Ting Mi, Hong Zhu, Junying Yuan, Jidong Zhu
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2018)
Article
Biochemistry & Molecular Biology
Zhenyi Su, Slawomir A. Dziedzic, Die Hu, Vica Jean Barrett, Nicole Broekema, Wanjin Li, Lihui Qian, Na Jia, Dimitry Ofengeim, Ayaz Najafov, Hong Zhu, David M. Knipe, Junying Yuan
CELL DEATH AND DIFFERENTIATION
(2019)
Article
Oncology
Ji Cao, Rong Dong, Li Jiang, Yanling Gong, Meng Yuan, Jieqiong You, Wen Meng, Zhanlei Chen, Ning Zhang, Qinjie Weng, Hong Zhu, Qiaojun He, Meidan Ying, Bo Yang
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Pharmacology & Pharmacy
Tong Xu, Chao Huang, Xiao-tian Qi, Xiao-chun Yang, Ning Zhang, Ji Cao, Chen Wang, Hong Zhu, Bo Yang, Qiao-jun He, Xue-jing Shao, Mei-dan Ying
EUROPEAN JOURNAL OF PHARMACOLOGY
(2019)
Article
Pharmacology & Pharmacy
Linlin Chang, Yan Hu, Yingying Fu, Tianyi Zhou, Jun You, Jiamin Du, Lin Zheng, Ji Cao, Meidan Ying, Xiaoyang Dai, Dan Su, Qiaojun He, Hong Zhu, Bo Yang
ACTA PHARMACEUTICA SINICA B
(2019)
Article
Chemistry, Multidisciplinary
Bin Lu, Xiao-bing Chen, Yu-cai Hong, Hong Zhu, Qiao-jun He, Bo Yang, Mei-dan Ying, Ji Cao
ACTA PHARMACOLOGICA SINICA
(2019)
Article
Chemistry, Multidisciplinary
Xue-jing Shao, Sen-feng Xiang, Ying-qian Chen, Ning Zhang, Ji Cao, Hong Zhu, Bo Yang, Qian Zhou, Mei-dan Ying, Qiao-jun He
ACTA PHARMACOLOGICA SINICA
(2019)
Review
Biochemistry & Molecular Biology
Fangjie Yan, Meijia Qian, Qiaojun He, Hong Zhu, Bo Yang
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
(2020)
Review
Pharmacology & Pharmacy
Xiaomeng Gao, Li Jiang, Yanling Gong, Xiaobing Chen, Meidan Ying, Hong Zhu, Qiaojun He, Bo Yang, Ji Cao
BRITISH JOURNAL OF PHARMACOLOGY
(2019)
Article
Oncology
Tao Yuan, Zibo Chen, Fangjie Yan, Meijia Qian, Hong Luo, Song Ye, Ji Cao, Meidan Ying, Xiaoyang Dai, Renhua Gai, Bo Yang, Qiaojun He, Hong Zhu
MOLECULAR ONCOLOGY
(2020)
Review
Pharmacology & Pharmacy
Xiaoxian Shi, Senfeng Xiang, Ji Cao, Hong Zhu, Bo Yang, Qiaojun He, Meidan Ying
PHARMACOLOGICAL RESEARCH
(2019)
Review
Pharmacology & Pharmacy
Aixiao Xu, Ning Zhang, Ji Cao, Hong Zhu, Bo Yang, Qiaojun He, Xuejing Shao, Meidan Ying
BIOCHEMICAL PHARMACOLOGY
(2020)
Article
Medicine, Research & Experimental
Jun Gao, Shixin Lin, Yao Gao, Xia Zou, Jun Zhu, Man Chen, Hong Wan, Hong Zhu
BIOMEDICINE & PHARMACOTHERAPY
(2019)